These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33079129)

  • 1. Functional analysis of a species-specific inhibitor selective for human Na+-coupled citrate transporter (NaCT/SLC13A5/mINDY).
    Higuchi K; Kopel JJ; Sivaprakasam S; Jaramillo-Martinez V; Sutton RB; Urbatsch IL; Ganapathy V
    Biochem J; 2020 Nov; 477(21):4149-4165. PubMed ID: 33079129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier.
    Kopel JJ; Bhutia YD; Sivaprakasam S; Ganapathy V
    Biochem J; 2021 Feb; 478(3):463-486. PubMed ID: 33544126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5).
    Huard K; Brown J; Jones JC; Cabral S; Futatsugi K; Gorgoglione M; Lanba A; Vera NB; Zhu Y; Yan Q; Zhou Y; Vernochet C; Riccardi K; Wolford A; Pirman D; Niosi M; Aspnes G; Herr M; Genung NE; Magee TV; Uccello DP; Loria P; Di L; Gosset JR; Hepworth D; Rolph T; Pfefferkorn JA; Erion DM
    Sci Rep; 2015 Dec; 5():17391. PubMed ID: 26620127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Membrane Na⁺-Coupled Citrate Transporter (SLC13A5) and Neonatal Epileptic Encephalopathy.
    Bhutia YD; Kopel JJ; Lawrence JJ; Neugebauer V; Ganapathy V
    Molecules; 2017 Feb; 22(3):. PubMed ID: 28264506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and inhibition mechanism of the human citrate transporter NaCT.
    Sauer DB; Song J; Wang B; Hilton JK; Karpowich NK; Mindell JA; Rice WJ; Wang DN
    Nature; 2021 Mar; 591(7848):157-161. PubMed ID: 33597751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Distinction between Human and Mouse Sodium-Coupled Citrate Transporters and Its Biologic Significance: An Attempt for Structural Basis Using a Homology Modeling Approach.
    Jaramillo-Martinez V; Urbatsch IL; Ganapathy V
    Chem Rev; 2021 May; 121(9):5359-5377. PubMed ID: 33040525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional features and genomic organization of mouse NaCT, a sodium-coupled transporter for tricarboxylic acid cycle intermediates.
    Inoue K; Fei YJ; Zhuang L; Gopal E; Miyauchi S; Ganapathy V
    Biochem J; 2004 Mar; 378(Pt 3):949-57. PubMed ID: 14656221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species-specific influence of lithium on the activity of SLC13A5 (NaCT): lithium-induced activation is specific for the transporter in primates.
    Gopal E; Babu E; Ramachandran S; Bhutia YD; Prasad PD; Ganapathy V
    J Pharmacol Exp Ther; 2015 Apr; 353(1):17-26. PubMed ID: 25617245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Na+ -coupled citrate transporter: primary structure, genomic organization, and transport function.
    Inoue K; Zhuang L; Ganapathy V
    Biochem Biophys Res Commun; 2002 Dec; 299(3):465-71. PubMed ID: 12445824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The longevity gene INDY (I'm Not Dead Yet) in metabolic control: Potential as pharmacological target.
    Willmes DM; Kurzbach A; Henke C; Schumann T; Zahn G; Heifetz A; Jordan J; Helfand SL; Birkenfeld AL
    Pharmacol Ther; 2018 May; 185():1-11. PubMed ID: 28987323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin.
    Kopel J; Higuchi K; Ristic B; Sato T; Ramachandran S; Ganapathy V
    Sci Rep; 2020 May; 10(1):8536. PubMed ID: 32444674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors.
    Pajor AM; de Oliveira CA; Song K; Huard K; Shanmugasundaram V; Erion DM
    Mol Pharmacol; 2016 Dec; 90(6):755-765. PubMed ID: 27683012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A home run for human NaCT/SLC13A5/INDY: cryo-EM structure and homology model to predict transport mechanisms, inhibitor interactions and mutational defects.
    Jaramillo-Martinez V; Ganapathy V; Urbatsch IL
    Biochem J; 2021 Jun; 478(11):2051-2057. PubMed ID: 34101804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus.
    Henke C; Töllner K; van Dijk RM; Miljanovic N; Cordes T; Twele F; Bröer S; Ziesak V; Rohde M; Hauck SM; Vogel C; Welzel L; Schumann T; Willmes DM; Kurzbach A; El-Agroudy NN; Bornstein SR; Schneider SA; Jordan J; Potschka H; Metallo CM; Köhling R; Birkenfeld AL; Löscher W
    Neurobiol Dis; 2020 Sep; 143():105018. PubMed ID: 32682952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, function, and expression pattern of a novel sodium-coupled citrate transporter (NaCT) cloned from mammalian brain.
    Inoue K; Zhuang L; Maddox DM; Smith SB; Ganapathy V
    J Biol Chem; 2002 Oct; 277(42):39469-76. PubMed ID: 12177002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.
    Brachs S; Winkel AF; Tang H; Birkenfeld AL; Brunner B; Jahn-Hofmann K; Margerie D; Ruetten H; Schmoll D; Spranger J
    Mol Metab; 2016 Nov; 5(11):1072-1082. PubMed ID: 27818933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological characterization of human and mouse sodium-dependent citrate transporters (NaCT/SLC13A5) reveal species differences with respect to substrate sensitivity and cation dependence.
    Zwart R; Peeva PM; Rong JX; Sher E
    J Pharmacol Exp Ther; 2015 Nov; 355(2):247-54. PubMed ID: 26324167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells.
    Li Z; Li D; Choi EY; Lapidus R; Zhang L; Huang SM; Shapiro P; Wang H
    J Biol Chem; 2017 Aug; 292(33):13890-13901. PubMed ID: 28655760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay.
    Klotz J; Porter BE; Colas C; Schlessinger A; Pajor AM
    Mol Med; 2016 May; 22():310-21. PubMed ID: 27261973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylhydrocarbon receptor-dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene-induced lipid accumulation in hepatocytes.
    Neuschäfer-Rube F; Schraplau A; Schewe B; Lieske S; Krützfeldt JM; Ringel S; Henkel J; Birkenfeld AL; Püschel GP
    Toxicology; 2015 Nov; 337():1-9. PubMed ID: 26303333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.